8-K: PDS Biotech Announces Positive Updated Results from Versatile-002 Trial at ESMO 2024

PDS Biotechnology reported updated data from its VERSATILE-002 trial, showing promising results for its Versamune HPV treatment in combination with pembrolizumab for head and neck cancer.

Summary

• PDS Biotechnology announced updated results from the VERSATILE-002 Phase 2 clinical trial.
• The trial evaluated Versamune HPV in combination with KEYTRUDA (pembrolizumab) as a first-line treatment for patients with HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma.
• The data was presented at the European Society for Medical Oncology (ESMO) Congress 2024.
• The median overall survival (mOS) remained at 30 months, with a lower 95% confidence interval of 19.7 months.
• The objective response rate (ORR) was 36%, with 19 out of 53 patients responding.
• The disease control rate (DCR) was 77%, with 41 out of 53 patients achieving disease control.
• 21% of patients experienced 90-100% tumor shrinkage.
• 5 out of 53 patients (9%) had a complete response.
• The treatment was generally well-tolerated, with Grade 3 adverse events seen in 9 patients.
• A Phase 3 clinical trial, VERSATILE-003, is planned to begin this year.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results, with significant improvements in survival and response rates compared to existing treatments. The planned Phase 3 trial also indicates a strong commitment to further development. However, the need for additional financing and the inherent risks of clinical trials temper the overall sentiment slightly.

Positives

• The combination therapy showed a significantly improved median overall survival compared to pembrolizumab alone.
• The objective response rate was notably higher than that of pembrolizumab alone.
• The disease control rate was high, indicating a good level of disease stabilization.
• A significant portion of patients experienced deep tumor shrinkage.
• The treatment was well-tolerated, with manageable adverse events.
• The company is planning to initiate a Phase 3 trial this year.

Negatives

• Grade 3 treatment-related adverse events were observed in 9 patients.
• The study is a single-arm Phase 2 trial, which may not be as robust as a randomized controlled trial.

Risks

• The company's ability to protect its intellectual property rights is a risk.
• The company is dependent on additional financing to fund its operations and complete the development and commercialization of its product candidates.
• There is a risk that raising additional capital may restrict the company's operations or require the company to relinquish rights to its technologies.
• The company has a limited operating history in its current line of business, making it difficult to evaluate its prospects.
• The timing and success of planned clinical trials are uncertain.
• The company's ability to continue as a going concern is a risk.

Future Outlook

The company plans to initiate the VERSATILE-003 Phase 3 clinical trial this year to further evaluate Versamune HPV plus pembrolizumab. They are also working on other combination therapies.

Management Comments

• Jared Weiss, M.D., stated that the data shows the strong clinical activity and durability of Versamune HPV plus pembrolizumab.
• Dr. Kirk Shepard, M.D., mentioned that responses continue to improve as the data from the VERSATILE-002 trial matures, suggesting durability of the Versamune HPV induced anti-tumor immune response.
• Dr. Shepard also expressed belief in the potential of the combination to be the first HPV-targeted immunotherapy for HNSCC.

Industry Context

The announcement is significant as it presents a potential new treatment option for HPV16-positive head and neck cancer, a challenging disease with limited treatment options. The results suggest that the combination therapy could offer a significant improvement over existing treatments like pembrolizumab alone.

Comparison to Industry Standards

• The median overall survival of 30 months with the combination therapy is significantly higher than the published 12-18 months for pembrolizumab monotherapy, as seen in studies by Harrington K. et al. and Licitra L. et al.
• The objective response rate of 36% is also notably higher than the 19-25% reported for pembrolizumab alone in the same studies.
• These results suggest that the combination therapy may be more effective than the current standard of care for this patient population.
• No head-to-head studies have been performed comparing Versamune HPV with other treatments.

Stakeholder Impact

• Shareholders may view the positive clinical trial results favorably.
• Patients with HPV16-positive head and neck cancer may benefit from a new treatment option.
• Employees may be encouraged by the progress of the company's research and development programs.
• The company's suppliers and partners may see increased business opportunities.

Next Steps

• The company plans to initiate the VERSATILE-003 Phase 3 clinical trial this year.
• The company will continue to evaluate the data from the VERSATILE-002 trial.
• The company is working on other combination therapies including PDS01ADC.

Key Dates

Keywords

PDS Biotechnology, Versamune HPV, KEYTRUDA, pembrolizumab, head and neck cancer, HNSCC, immunotherapy, clinical trial, ESMO, VERSATILE-002, VERSATILE-003, oncology